Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Cost-benefit analysis of endocrine therapy in the adjuvant setting for postmenopausal patients with hormone receptor-positive breast cancer, based on survival data and future prices for generic drugs in the context of the German health care system
Author: Lux, M.
Reichelt, C.
Karnon, J.
Tanzer, T.
Radosavac, D.
Fasching, P.
Beckmann, M.
Thiel, F.
Citation: Breast Care, 2011; 6(5):381-389
Publisher: Karger
Issue Date: 2011
ISSN: 1661-3791
Statement of
Michael P. Lux, Claudia Reichelt, Jon Karnon, Thorsten D. Tänzer, Dragan Radosavac, Peter A. Fasching, Matthias W. Beckmann, Falk C. Thiel
Keywords: Letrozole; Anastrozole; Tamoxifen; Cost-effectiveness; QALY; BIG 1-98; ATAC
Rights: Copyright © 2011 S. Karger AG, Basel
RMID: 0020115137
DOI: 10.1159/000333118
Appears in Collections:Public Health publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.